Chemotherapy-Induced Anemia Clinical Landscape Market Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Chemotherapy-Induced Anemia” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The prevalence proportions of CIA and the severity of anemia vary by region, cancer type, and stage.

All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.

There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase. These drugs are administered via the intravenous and oral routes.

The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 22.5%, and the average probability a drug advances from Phase III is 82.5%. Drugs, on average, take 10.1 years from Phase I to approval, compared to 9.2 years in the overall hematology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III-IV, and 39% in Phase I-II.

Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 66 trials.

Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Disease definition
• Patient subtypes
• Symptoms
• Risk factors
• Diagnosis

TREATMENT

• Iron supplements
• Blood transfusion
• Erythropoietin-stimulating agents (ESAs)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• Roxadustat for CIA (December 9, 2019)

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

BIBLIOGRAPHY

• Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/1v8lep

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900